EUVIMEDEUVIMED entdecken
Crossref

Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy

Xinyuan Ye, Huiting Qin, Wei Zhang, Chuanxiang Yao, Xinyue Zheng, Siying Zheng, Ying Xiong, Chenyue Zhu, Lili Jiang, Shuailong Jia, Hongliang Jiang, Zhifeng Du

Drug Metabolism and Disposition · 2026

DOI: 10.1016/j.dmd.2026.100371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Xinyuan Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Disulfides, Proteomics, Insulin, Long-Acting, Insulin Glargine. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disulfide bonds are conserved structural determinants in peptides, reinforcing conformational integrity and stability. Peptides constrained by disulfide bonds resist enzymatic cleavage and exhibit suppressed b/y-ion formation in bottom-up mass spectrometry. Furthermore, disulfide bond reshuffling is often overlooked by existing software, leading to incomplete metabolite identification and inaccurate mapping of metabolic soft spots. Current tools reliably identify peptides containing native or nonnative disulfide bonds, but fail to resolve peptides with highly cross-linked disulfide architectures. To address this gap, an integrated analytical strategy combining established proteomic workflow with product ion filtering was developed based on previous work. Linaclotide, insulin glargine, and insulin degludec were selected as representative peptide drugs. First, the integrated strategy's feasibility was verified using pepsin-digested linaclotide. Subsequently, the strategy was employed to map metabolic soft spots of therapeutic peptides across multiple human biological matrices. From linaclotide digests, 3 peptic fragments were confidently identified, whereas 1 in-source fragmentation artifact was excluded based on diagnostic neutral losses and retention time alignment. In human liver S9 incubation, 6 metabolites were identified with high-confidence spectral matches, and 7 metabolites were characterized in human intestinal S9 incubation, enabling unambiguous localization of linaclotide's metabolic soft spots. In addition, analysis of insulin glargine in human serum under in vitro incubation conditions identified 20 metabolites and 3 in-source fragmentation artifacts, with metabolic soft spots unambiguously assigned. Notably, 95 metabolites of insulin degludec, along with their metabolic soft spots, were mapped using the strategy, including 4 peptides containing glutamic-C16 fatty diacid that were identified by product ion filtering. SIGNIFICANCE STATEMENT: To our knowledge, this study represents the first comprehensive identification of the metabolic soft spots of linaclotide and insulin degludec across physiologically relevant enzymatic systems and biological matrices. Reduction and alkylation eliminate analytical complexity from cross-linked disulfide architectures, enabling comprehensive peptide metabolite characterization. This study provides a transferable, integrated analytical strategy for the comprehensive identification of metabolic soft spots and metabolites in other peptides with highly cross-linked disulfide bonds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DisulfidesProteomicsInsulin, Long-ActingInsulin GlarginePeptidesHumansTandem Mass SpectrometryMass SpectrometryWorkflow

Stichwörter der Autor:innen

Disulfide bondsInsulin degludecInsulin glargineLinaclotideMetabolic soft spots

Substanzen

DisulfidesInsulin, Long-ActingInsulin GlarginePeptidesinsulin degludec

Autor:innen und Institutionen

  • Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: jsl1993521@163.com.
  • Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, China. Electronic address: jianghongliang@hust.edu.cn.
  • Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan, China. Electronic address: duzhifeng@hust.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ye, X., Qin, H., Zhang, W., Yao, C., Zheng, X., Zheng, S., Xiong, Y., Zhu, C., Jiang, L., Jia, S., Jiang, H., & Du, Z. (2026). Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2026.100371

Vancouver

Ye X, Qin H, Zhang W, Yao C, Zheng X, Zheng S, et al. Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2026.100371

BibTeX
@article{Ye2026,
  author = {Ye, Xinyuan and Qin, Huiting and Zhang, Wei and Yao, Chuanxiang and Zheng, Xinyue and Zheng, Siying and Xiong, Ying and Zhu, Chenyue and Jiang, Lili and Jia, Shuailong and Jiang, Hongliang and Du, Zhifeng},
  title = {Rapid and comprehensive identification of the metabolic soft spots of peptide drugs with highly cross-linked disulfide bonds by integrating established proteomic workflow with a product ion filtering strategy},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  doi = {10.1016/j.dmd.2026.100371}
}
Kostenlos starten →